Sapient Joins the Foundation for the National Institutes of Health Biomarkers Consortium

San Diego, CA—Sapient, a biomarker discovery organization transforming drug development through rapid, large-scale biomarker profiling, has joined the Foundation for the National Institutes of Health (FNIHBiomarkers Consortium, the preeminent group of public-private partners focused on identifying, developing, and qualifying biomarkers to improve drug development and regulatory decision-making. Sapient’s Philip Worboys, PhD, Head of Translational Science, and Tanya Nguyen, PhD, Head of Scientific Operations, will be participating in the Consortium’s Steering Committees that guide specific projects in Cancer, Inflammation & Immunity, Metabolic Disorders, and Neuroscience.

Founded by the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and Pharmaceutical Research and Manufacturers of America (PhRMA), the Biomarkers Consortium brings together constituents from industry, government, foundations, professional associations, and patient advocacy organizations in cross-sector efforts to accelerate development and approval of biomarkers that improve clinical practice. As a Biomarkers Consortium collaborator, Sapient will work alongside these organizations and contribute scientific and technical expertise to support programs aimed at delivering new biomarker-based tools and treatments.

fnih biomarkers consortium member

“Sapient shares in the mission of the FNIH Biomarker Consortium. As an organization, we are fully focused on accelerating the speed and scale of biomarker discovery, because we understand the transformational potential that biomarkers have to make drug development more efficient, successful, and ultimately, to drive better patient care,” said Dr. Worboys. “We’re excited to collaborate with the consortium members across industry, academia, and government who also see this immense value, and to contribute our knowledge and unique technology to support biomarker advancements.”

“FNIH Biomarkers Consortium members are realizing the new era of predictive, personalized medicine through biomarker research,” added Dr. Nguyen. “We look forward to working with these organizations to share best practices in biomarker discovery, and to contribute directly to important programs aimed at identifying and validating high-impact biomarkers.”


About Sapient

Sapient is an end-to-end biomarker discovery partner for pharmaceutical and biotechnology sponsors, providing solutions from large-scale untargeted discovery screening through development of targeted, quantitative CLIA assays to support drug programs at every phase. Its platform combines advanced mass spectrometry technologies – able to assay >11,000 molecules per biosample – computational learning, and an expansive proprietary Human Biology Database of several hundred thousand biosamples to discover circulating biomarkers at unprecedented speed and scale, and rapidly deliver actionable insights that align patients, disease biology, and specific therapies.

These methods reduce the time and complexity of biomarker discovery and validation, and drive greater understanding of biological processes, disease progression, and drug responsiveness to optimize drug pipelines for success and accelerate clinical development. For more information, visit

About the Biomarkers Consortium at the Foundation for the National Institutes of Health (FNIH)

The Foundation for the National Institutes of Health (FNIH) creates and manages alliances with public and private institutions in support of the mission of the National Institutes of Health (NIH), the world’s premier medical research agency. The Biomarkers Consortium at FNIH is the preeminent public-private partnership focused on developing biomarkers that accelerate therapeutics and improve clinical care. The Biomarkers Consortium brings together government, industry, patient advocacy groups, and not-for-profit organizations to address one of the most pressing needs in the diagnosis and treatment of disease: the development and the seeking of regulatory approval for disease biomarkers and surrogates. For more information, visit

Media Contact:
Carla Nieser
Head of Marketing, Sapient